Monte Rosa Therapeutics (GLUE) Change in Acquisitions & Divestments (2022 - 2026)

Monte Rosa Therapeutics' Change in Acquisitions & Divestments history runs 5 years deep, the most recent figure standing at $72.9 million for Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments rose 85.08% year-over-year to $72.9 million in Q1 2026; TTM through Mar 2026 was $313.0 million, a 93.28% increase from a year earlier, with the FY2025 full-year figure at $279.5 million, up 47.21% from the prior year.
• Change in Acquisitions & Divestments fell to $72.9 million in Q1 2026 per GLUE's latest filing, from $89.4 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $130.3 million in Q3 2022 and bottomed at -$130.3 million in Q4 2022.
• The 5-year median for Change in Acquisitions & Divestments is $46.1 million (2025), against an average of $47.2 million.
• Across the five-year window, Change in Acquisitions & Divestments sank 123.84% in 2023 and surged 326.98% in 2024, its largest moves.
• Year by year, Change in Acquisitions & Divestments stood at -$130.3 million in 2022, then jumped by 191.84% to $119.7 million in 2023, then plunged by 68.87% to $37.2 million in 2024, then jumped by 139.91% to $89.4 million in 2025, then declined by 18.46% to $72.9 million in 2026.
• Per Business Quant, the three latest GLUE Change in Acquisitions & Divestments figures stand at $72.9 million (Q1 2026), $89.4 million (Q4 2025), and $104.8 million (Q3 2025).